Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
80070.000.2873%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

NervGen Pharma Corp

NGENNASDAQ
Trade with Public
Trade with Public
$2.33
0.010.43%
At close: Sep 4, 5:00 PM EST
$2.31
-0.02-0.86%
After Hours: Sep 4, 8:45 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentCompareOptionsStock Report

NervGen Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for NervGen Pharma (NGEN).

Price Target Range — 2 Quarters

Analyst Consensus — 2 Analysts

2Buy
Consensus RatingBuy# Analysts2Avg. Consensus PT$13Upside to Avg. PT+441.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 14, 2026HC Wainwright & Co.Raghuram SelvarajuPT CutBuy$18→$15
Jul 13, 2026Leerink PartnersMarc GoodmanInitiateOutperform$10
More with Benzinga EdgeGet Access

Analyst Ratings News

Micron To Rally Around 87%? Here Are 10 Top Analyst Forecasts For Tuesday

Summary: Wall Street analysts changed rating for JAZZ, AFRM, MNDY, NGEN, FCEL, RRR, ABNB, KARO. See how other analysts view these stocks.
Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on NervGen Pharma, Lowers Price Target to $15

HC Wainwright & Co. analyst Raghuram Selvaraju maintains NervGen Pharma (NASDAQ:NGEN) with a Buy and lowers the price target from $18 to $15.
Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On NervGen Pharma with Outperform Rating, Announces Price Target of $10

Leerink Partners analyst Marc Goodman initiates coverage on NervGen Pharma (NASDAQ:NGEN) with a Outperform rating and announces Price Target of $10.
Benzinga Newsdesk

This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed outlook on top names. See analyst rating changes, including upgrades/downgrades/initiations, on Benzinga.
Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On NervGen Pharma with Buy Rating, Announces Price Target of $18

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on NervGen Pharma (NASDAQ:NGEN) with a Buy rating and announces Price Target of $18.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved